Synchronous lung and multiple soft tissue metastases developed from osteosarcoma of tibia: a rare case report and genetic profile analysis

Chuanxi Zheng1†, Yitian Wang1†, Yi Luo1, Zongguo Pang2, Yong Zhou1*, Li Min1 and Chongqi Tu1*

Abstract

Background: Osteosarcoma is the most common primary malignant bone tumor with a highly metastatic propensity in children and young adolescents. The majority of metastases develop in the lung, while metastases to the extrapulmonary locations have rarely been discussed, especially in skeletal muscle.

Case presentation: We reported a young patient with pathologically diagnosed osteosarcoma of the right tibia who was initially treated with standard chemotherapy and complete surgical resection. However, pulmonary metastases and multiple soft tissue masses in skeletal muscle developed four years after the index surgical resection. Subsequently, a targeted next-generation sequencing assay based on an 806 oncogenes and tumor suppressor genes panel was performed to analyze genetic alterations in this patient with rare metastatic pattern. The genetic analysis revealed canonical somatic mutations of RB1 and germline variants of ALK (c.862 T > C), BLM (c.1021C > T), PTCH1 (c.152_154del), MSH2 (c.14C > A), RAD51C (c.635G > A). Using silico prediction programs, the germline variants of MSH2 and RAD51C were predicted as "Possibly Damaging" by Polymorphism Phenotyping v2 (PolyPhen-2) and "Tolerated" by Sorting Intolerant from Tolerant (SIFT); BLM was classified as "Tolerated", while the germline variant of ALK was predicted to be pathogenic by both PolyPhen-2 and SIFT.

Conclusions: Osteosarcoma with extrapulmonary metastases is rare, especially located in the skeletal muscle, which predicts a worse clinical outcome compared with lung-only metastases. The several novel variants of ALK, BLM, PTCH1 in this patient might expand the mutational spectrums of the osteosarcoma. All the results may contribute to a better understanding of the clinical course and genetic characteristics of osteosarcoma patients with metastasis.

Keywords: Osteosarcoma, Extrapulmonary, Metastasis, Germline mutation, ALK
5-year overall survival rate of those patients is usually less than 30% [3–7]. The majority of osteosarcoma metastases occur in the lung, while metastases to the extrapulmonary locations have been rarely reported, such as breast, abdominal viscera, chest wall, heart, penis, brain, subcutaneous tissue, skeletal muscle [8–15]. Among these extrapulmonary involvement, skeletal muscle metastases are extremely rare which account for only 1.6% of patients with metastases from osteosarcoma and there are only several relevant case reports that have been published to date [16].

The clinical outcome of the patients with extrapulmonary metastases is much worse than that of the patients with lung-only metastases [16]. For patients with resectable lung metastases, the combination of aggressive chemotherapy with metastasectomy could effectively achieve disease control and improve the prognosis, whereas systematic chemotherapy seems invalid for patients who have developed extrapulmonary metastases [8, 16]. The dismal outcome of patients with extrapulmonary metastases emphasized the importance of understanding the underlying molecular mechanisms and specific genetic profile of this metastatic pattern, which so far remain unknown. To our knowledge, none of the published cases had investigated the genetic profile of the patient with skeletal muscle metastasis from osteosarcoma. Here, we reported a case of patient with osteosarcoma who developed skeletal metastases four years after the initial treatment. Synchronously, we investigated the molecular genetic profile of tumors sample in an effort to better understand the clinical course and genetic characteristics of osteosarcoma patients with soft tissue metastasis.

Case presentation
A 17-year-old young patient with a one-month history of dull pain and limited motion of the right knee was admitted to the orthopedic department of West China Hospital in July 2016. The patient reported no relevant oncological family history. Physical examination revealed tenderness in the medial metaphysis of the right tibia and limited mobility of the right knee. The anteroposterior and lateral radiograph showed an ill-defined osteolytic lesion with osteoid matrix involving the proximal metaphysis of the right tibia (Fig. 1A). Magnetic resonance imaging (MRI) revealed an intramedullary lesion of heterogeneously high signal intensity with cortical breaching and soft tissue extension. Bone scintigraphy (C) presented diffusely increased activity in the right proximal tibia. (D) Pathological examination of the biopsy specimen revealed severe cytological atypia and regions of the eosinophilic chondroid matrix with chondroblastoma-like neoplastic cells (1) and neoplastic bone production (2).

Fig. 1 The radiological and histological findings of the primary osteosarcoma in the right tibia. Anteroposterior and lateral radiograph showed (A) an ill-defined osteolytic lesion with osteoid matrix involving the proximal metaphysis of the right tibia. Coronal fat-saturated T2-weighted MRI image (B) demonstrated an intramedullary lesion of heterogeneously high signal intensity with cortical breaching and soft tissue extension. Bone scintigraphy (C) presented diffusely increased activity in the right proximal tibia. (D) Pathological examination of the biopsy specimen revealed severe cytological atypia and regions of the eosinophilic chondroid matrix with chondroblastoma-like neoplastic cells (1) and neoplastic bone production (2)
soft tissue extension in the proximal metaphysis of the right tibia (Fig. 1B). Computed tomography (CT) scan of the chest did not find the distant metastasis and bone scintigraphy only presented diffusely increased activity in the right proximal tibia (Fig. 1C). Subsequently, an incisional biopsy of lesion in the right tibia was performed. The pathological findings revealed severe cytological atypia and regions of the eosinophilic chondroid matrix with chondroblastoma-like neoplastic cells and osteoid formation, which confirmed the diagnosis of chondroblastoma-like osteosarcoma (Fig. 1D). After three courses of neoadjuvant chemotherapy consisting of doxorubicin (30 mg/m² on days 1 to 2) and cisplatin (120 mg/m² on day 1), the patient underwent segmental resection of the lesion with prosthetic reconstruction. While the histological response rate of the resected specimen was less than 50% of the entire lesion, indicating the patient might be refractory to the first-line neoadjuvant chemotherapy. Following surgery, the second-line adjuvant chemotherapy consisting of doxorubicin (30 mg/m² on days 1 to 2), cisplatin (120 mg/m² on day 1) and ifosfamide (3 g/m² on days 1 to 4) were administrated. However, it was discontinued after two courses of treatment due to patient refusal and substituted by the anti-angiogenesis therapy with apatinib, an oral tyrosine kinase inhibitor. Initially, apatinib was administrated at an initial dose of 500 mg once daily with informed consent for off-label use. Due to the drug-related toxicity of the wound dehiscence and hair hypopigmentation, the patient discontinued apatinib treatment after two months by his own decision and then lost to the periodic clinical assessment in the subsequent follow-up.

Unfortunately, the patient presented to our orthopedic clinic again with a complaint of polypnea and multiple soft tissue masses in the right hand and left buttock in April 2020. Physical examination revealed multiple firm, palpable, tender masses in the right shoulder, forearm, left buttock, and the 2, 3, 4, 5 digits of the right hand, without any local recurrence around the right knee (Fig. 2A, D, H, L). The CT scan of whole body demonstrated multiple soft masses without bone destruction in the right deltoid muscle, right forearm, left gluteal maximus muscle, and the 2, 3, 4, 5 digits of the right hand (Fig. 2B, C, E, F, G, I, J). Single-photon emission computed tomography revealed multiple pulmonary metastatic lesions in the bilateral lung in which the largest nodule measuring 7.6 cm × 4.2 cm × 5.0 cm was located in the left upper lobe with internal calcification (Fig. 3A).
Bone scintigraphy indicated increased activity lesions in the sites corresponding to the nodule in the left lung (Fig. 3B). An incisional biopsy of lesion in the left gluteal maximus muscle was conducted, the pathological findings showed atypical cell proliferation and osteoid formation consistent with the microscopic presence of osteosarcoma. Based on the medical history, radiological and pathological findings, the diagnosis of multiple metastases from osteosarcoma in the bilateral lung and skeletal muscles was established. Nevertheless, the subsequent Eastern Cooperative Oncology Group (ECOG) performance score of the patient was 3 indicating a poor tolerance for palliative chemotherapy and his family was also counseled on the poor prognosis of the disease. Eventually, the patient and his family were reluctant to undergo palliative chemotherapy and decided to pursue another further targeted treatment.

**Genomic analysis**

To further investigate genetic alterations of this rare case, somatic tumor testing on soft tissue metastasis was performed. Tumor DNA was extracted from the fresh biopsies of tumor cells (frozen in liquid nitrogen, and stored at -80°C) using DNA Extraction Reagent Kit (TIANGEN, Beijing, China). Meanwhile, genomic DNA was extracted from whole peripheral blood using standard phenol–chloroform extraction protocol to aid in determining germline variants. The cancer-specific mutation status was evaluated with the next-generation DNA sequencing for 806 oncogenes and tumor suppressor genes from the cancer panel (illumina NovaSeq 6000 System, United States).

Sequencing analysis of the sample acquired from the gluteal metastasis revealed a microsatellite-stable tumor with a low tumor mutational burden (1.02 mut/MB) and immunohistochemical staining was negative for PD-L1 expression. Genes with alternation in the tumor sample were summarized in Table 1. Panel sequencing analysis of the 806 genes identified previously reported somatic mutation in **RB1**, exon 21 c.2211+1G>C (COSM7154357, COSM7154356), as well as heterozygous germline mutation in **MSH2** exon1, c.14C>A/ p.P5Q (dbSNP:rs148098584) and **RAD51C**, exon4, c.635G>A/ p.R212H (dbSNP:rs200857129). Importantly, the therapeutic implication of the somatic mutation in **RB1** indicated the patient might be sensitive to mTOR inhibitors. Above the aforementioned variants, several rare germline variants of **ALK** (exon3, c.862T>C/p.W288R), **BLM** (exon5, c.1021C>T/p.L341F), **PTCH1** (exon1, c.152_154del/p.51_52del) were also identified in this patient (Fig. 4). These variants were further assessed for possible pathogenicity and the effects on protein function.
by using the bioinformatic programs, including Sorting Intolerant from Tolerant (SIFT), Polymorphism Phenotyping v2 (PolyPhen-2). Among the genetic alterations, germline variants of the PTCH1, MSH2 and RAD51C were predicted as “Possibly Damaging” by Polyphen-2 and “Tolerated” by SIFT; BLM was classified as “Tolerated”, while the germline variant of ALK was predicted to be damaging by both PolyPhen-2 and SIFT. However, all five germline mutations in the tumor sample were classified as variants of uncertain significance (VUS) in ClinVar (http://www.ncbi.nlm.nih.gov/clinvar). Based on the therapeutic implication of somatic mutation in the RB1 which might be sensitive to the targeted therapy of mTOR inhibitor, and everolimus was orally administrated with a dose of 10mg daily. However, the disease still progressed rapidly and the patient died from the complication of lung metastasis 2 months later.

**Discussion and Conclusion**

Due to the resistant mechanism of skeletal muscle to metastatic deposits, metastases to soft tissue from primary malignancies are rare [17]. In osteosarcoma, skeletal muscle metastases are extremity rare accounting for about 1.6% of patients who developed metastatic lesions from primary sites [16]. Since the introduction of chemotherapy, the metastatic pattern of osteosarcoma has altered with a higher incidence of extrapulmonary metastases in patients who underwent adjuvant chemotherapy, with or without concurrent pulmonary metastases [18]. While the clinical features, therapeutic strategies and prognosis between the patients with lung-only and extrapulmonary lesions are markedly distinct. The latter metastatic pattern usually indicates the probability of disease dissemination, a poor histologic response to preoperative chemotherapy and difficulty in complete resection of metastatic lesions, which are associated with worse clinical outcomes [19, 20]. The median overall survival was 26.0 months for those with lung-only metastasis, but only 12.7 months for patients who developed extrapulmonary metastasis [16]. In the present case, the patient was resistant to the first-line chemotherapy with a histological response rate of less than 90% that was similar to the previously reported cases with skeletal muscle metastases [8, 20]. As the second-line therapy, additional ifosfamide chemotherapy was administrated, whereas it seemed insufficient to control disease progression. Although oral tyrosine kinase inhibitors apatinib had been demonstrated effective in the management of advanced osteosarcoma after the failure of multimodal therapy [21], the patient terminated apatinib treatment within two months due to the intolerable adverse effects. Consequently, the patient developed multiple metastases in the bilateral lung and skeletal muscles. In this setting, the intensive chemotherapy combined with aggressive metastasectomy was not feasible leading to a dismal clinical prognosis.

Unlike other solid tumors, osteosarcoma exhibits chromosomal instability characterized by intra-tumoral and inter-tumoral heterogeneity with a higher mutation rate [22]. Several cancer predisposition syndromes have been established to be associated with osteosarcoma, including Li-Fraumeni syndrome and Diamond-Blackfan anemia, Rothmund-Thomson syndrome, Baller-Gerold syndrome, RAPADILINO syndrome, Werner syndrome, Bloom syndrome, ATR-X syndrome [23–28]. In addition to the syndrome-related osteosarcoma, increasing pathogenic germline mutation has been identified in osteosarcoma individuals with use of the DNA sequencing which may contribute to the complex underlying mechanism of osteosarcoma development. A sequencing study of 1120 cases showed 7/39 osteosarcoma patients harboring pathogenic and likely pathogenic variants in TP53, RB1, APC, MSH2, and PALB2 [29]. Another targeted exon sequencing study involving 1162 patients with sarcoma

### Table 1 Genes with alteration in the sample from the skeletal muscle metastasis of the patient

| Gene | Location | Nucleotide change | Amino acid change | Gene ID in databases | Mutation pattern | SIFT function | Polyphen-2 function | Therapeutic implication |
|------|----------|-------------------|-------------------|----------------------|-----------------|--------------|---------------------|------------------------|
| **Somatic mutations** | | | | | | | | |
| RB1  | exon21  | c.2211 + 1G > C   | NA                | COSM7154357          | Splicing        | NA           | NA                  | mTOR inhibitor          |
| **Germline mutation** | | | | | | | | |
| ALK  | exon3   | c.862T > C        | p.W288R           | NA                   | Heterozygosis   | Damaging     | Damaging            | VUS                    |
| BLM  | exon5   | c.1021C>T         | p.L341F           | NA                   | Heterozygosis   | Tolerated    | Benign              | VUS                    |
| PTCH1| exon1   | c.152_154del      | p.S1_2del         | NA                   | Heterozygosis   | Tolerated    | Damaging            | VUS                    |
| MSH2 | exon1   | c.14C>A           | p.P5Q             | rs56170584           | Heterozygosis   | Tolerated    | Damaging            | VUS                    |
| RAD51C| exon4   | c.635G>A          | p.R212H           | rs200857129          | Heterozygosis   | Tolerated    | Damaging            | VUS                    |

NA not achieved, VUS variant of uncertain significance
revealed that more than 50% of all patients carried pathogenic variants in TP53, BRCA2, ATM, ATR, and ERCC2 [30]. More recently, an emerging study investigating the germline genetic architecture of 1244 patients with osteosarcoma demonstrated that 28% of patients possessed pathogenic or likely pathogenic cancer-susceptibility genes variants and identified new candidate genes including CDKN2A, MEN1, VHL, POT1, APC, MSH2 and ATRX [31]. In the present case, we likewise identified the heterozygous mutation in MSH2, RAD51C as previously reported in osteosarcoma [31]. Furthermore, we observed several novel germline variants of ALK (c.862 T > C), BLM (c.1021C > T), PTCH1 (c.152_154del) in this patient. However, only the germline variant of ALK was predicted to be pathogenic by using in silico prediction programs.
Aberrations in the oncogene ALK have emerged as potentially relevant biomarkers and therapeutic targets in several solid tumors, including neuroblastoma, inflammatory myofibroblastic tumor, and non-small-cell lung cancer [32]. Moreover, the ALK has been found to be rearranged, mutated, or amplified in Ewing sarcoma and rhabdomyosarcoma [32–34]. The immunopositivity expression of ALK protein was also observed in 30%–40% of patients with soft tissue sarcoma (including osteosarcoma) and correlated with a poor clinical course [35, 36]. In the synovial sarcoma cell lines, the ALK variant with a large extracellular domain deletion encoding by the absence of exons 2–17 and exon1-exon18 splicing was identified as a novel driver gene [37]. Subsequent functional analysis demonstrated this alteration activated multiple proliferative and survival pathways, resulting in a remarkable dependency on ALK for tumor cells growth both in vitro and in vivo [37]. Moreover, ALK-positive patients harboring ALK rearrangement in both primary synovial sarcoma and metastatic lesions further validated the role of ALK in synovial sarcoma and indicated ALK aberration may be required for metastatic progression [37]. Recently, a novel ALK transcript initiated from a de novo alternative transcription initiation (ATI) site in ALK intron 19, ALKATI, was frequently detected in soft tissue sarcoma [36]. In vitro and vivo, ALKATI drove tumorogenesis and enhanced cancer stem cell-like properties through interacting with c-Myc and promoting the binding of c-Myc to the ABCG2 promoter [36]. So far, few studies have systematically investigated the role of ALK in osteosarcoma, although somatic ALK loss (c.*60_*61insCAAT) and mutation (p.K911T and p.A585T) have been reported in human osteosarcoma samples [38, 39]. However, these aforementioned results implied ALK alteration might play an important role in the tumor progression of osteosarcoma.

Importantly, ALK mutation or rearrangement has been shown to lead to resistance of tumor cells to both radiotherapy and chemotherapy, but sensitiveness to ALK inhibitors [36, 37]. Several tyrosine kinase inhibitors targeting ALK were recently validated in clinical trials, such as brigatinib, crizotinib and ceritinib which have been approved by the Food and Drug Administration (FDA) for the management of inflammatory myofibroblastic tumors with ALK translocation [40, 41]. Mosse and colleagues have reported 86% of patients with ALK-fusion inflammatory myofibroblastic tumors responded to crizotinib and 36% of patients achieved a complete response [42]. Moreover, Jiao et al. reported a patient with metastatic low-grade sarcoma carrying CARS-ALK fusion who was dramatically responded to multiple ALK tyrosine kinase inhibitors (crizotinib and alectinib) after treatment failure of the first-line chemotherapy and successfully survived for more than 5 years with a durable response [43]. In this context, we speculated whether the present patient with mutation of ALK could benefit from ALK inhibitors treatment after failure of chemotherapy, which might halt the disease progression or improve the survival of the patient to some extent. However, the efficacy and potential benefit of ALK inhibitors in the adjuvant setting for osteosarcoma require further confirmation in future studies.

In conclusion, osteosarcoma with extrapolmonary metastases is rare, especially in the skeletal muscle, which predicts a worse clinical outcome compared with lung-only metastases. Additionally, several novel mutations have been identified in this study which would enrich the mutational spectrums of osteosarcoma. More information about the biological relevance of these mutations will be helpful to shed new light on the therapeutic targets for this refractory disease.

Acknowledgements
Not Applicable

Authors’ contributions
CXZ and YTW conducted a literature search and drafted the manuscript. YL and LM were involved in the management of the patient. ZGP was involved in the pathological diagnosis of the mass. CQT and YZ contributed to the manuscript review. CXZ wrote the final version of the manuscript. The authors read and approved the final manuscript.

Funding
This work was supported by the National Key Research and Development Program of China (No. 2017YFB0702604, Dr. Zhou) and the National Natural Science Foundation of China (No. 81801852, Dr. Zhou) for patient follow-up costs and data collection costs.

Availability of data and materials
All data used or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
This study was approved by the ethics committee of the West China Hospital, Sichuan University, Chengdu, People’s Republic of China, and was permitted to be published. Written informed consent to have the case details and accompanying images published was obtained from the patient. All clinical investigations were conducted following the principles expressed in the Declaration of Helsinki.

Consent for publication
The written consent to publish images or other personal or clinical details of participants was obtained from the patient and patient’s parent. A copy of written consent is available for review.

Competing interests
The authors declare that they have no conflict of interest.

Author details
1 Department of Orthopedics, Orthopedics Research Institute, West China Hospital, Sichuan University, Guoxue Road No. 37, Chengdu, Sichuan 610041, People’s Republic of China. 2 Department of Pathology, West China Hospital, Sichuan University, Guoxue Road No. 37, Chengdu, Sichuan 610041, People’s Republic of China.


c-Myc
promoter
ABCG2
translation (ATI) site in ALK intron 19, ALKATI, was frequently detected in soft tissue sarcoma [36]. In vitro and vivo, ALKATI drove tumorogenesis and enhanced cancer stem cell-like properties through interacting with c-Myc and promoting the binding of c-Myc to the ABCG2 promoter [36]. So far, few studies have systematically investigated the role of ALK in osteosarcoma, although somatic ALK loss (c.*60_*61insCAAT) and mutation (p.K911T and p.A585T) have been reported in human osteosarcoma samples [38, 39]. However, these aforementioned results implied ALK alteration might play an important role in the tumor progression of osteosarcoma.

Importantly, ALK mutation or rearrangement has been shown to lead to resistance of tumor cells to both radiotherapy and chemotherapy, but sensitiveness to ALK inhibitors [36, 37]. Several tyrosine kinase inhibitors targeting ALK were recently validated in clinical trials, such as brigatinib, crizotinib and ceritinib which have been approved by the Food and Drug Administration (FDA) for the management of inflammatory myofibroblastic tumors with ALK translocation [40, 41]. Mosse and colleagues have reported 86% of patients with ALK-fusion inflammatory myofibroblastic tumors responded to crizotinib and 36% of patients achieved a complete response [42]. Moreover, Jiao et al. reported a patient with metastatic low-grade sarcoma carrying CARS-ALK fusion who was dramatically responded to multiple ALK tyrosine kinase inhibitors (crizotinib and alectinib) after treatment failure of the first-line chemotherapy and successfully survived for more than 5 years with a durable response [43]. In this context, we speculated whether the present patient with mutation of ALK could benefit from ALK inhibitors treatment after failure of chemotherapy, which might halt the disease progression or improve the survival of the patient to some extent. However, the efficacy and potential benefit of ALK inhibitors in the adjuvant setting for osteosarcoma require further confirmation in future studies.

In conclusion, osteosarcoma with extrapolmonary metastases is rare, especially in the skeletal muscle, which predicts a worse clinical outcome compared with lung-only metastases. Additionally, several novel mutations have been identified in this study which would enrich the mutational spectrums of osteosarcoma. More information about the biological relevance of these mutations will be helpful to shed new light on the therapeutic targets for this refractory disease.

Acknowledgements
Not Applicable

Authors’ contributions
CXZ and YTW conducted a literature search and drafted the manuscript. YL and LM were involved in the management of the patient. ZGP was involved in the pathological diagnosis of the mass. CQT and YZ contributed to the manuscript review. CXZ wrote the final version of the manuscript. The authors read and approved the final manuscript.

Funding
This work was supported by the National Key Research and Development Program of China (No. 2017YFB0702604, Dr. Zhou) and the National Natural Science Foundation of China (No. 81801852, Dr. Zhou) for patient follow-up costs and data collection costs.

Availability of data and materials
All data used or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
This study was approved by the ethics committee of the West China Hospital, Sichuan University, Chengdu, People’s Republic of China, and was permitted to be published. Written informed consent to have the case details and accompanying images published was obtained from the patient. All clinical investigations were conducted following the principles expressed in the Declaration of Helsinki.

Consent for publication
The written consent to publish images or other personal or clinical details of participants was obtained from the patient and patient’s parent. A copy of written consent is available for review.

Competing interests
The authors declare that they have no conflict of interest.

Author details
1 Department of Orthopedics, Orthopedics Research Institute, West China Hospital, Sichuan University, Guoxue Road No. 37, Chengdu, Sichuan 610041, People’s Republic of China. 2 Department of Pathology, West China Hospital, Sichuan University, Guoxue Road No. 37, Chengdu, Sichuan 610041, People’s Republic of China.
Yamada K, Yatabe Y, Sugiura H. Osteosarcoma with skeletal muscle metastasis. Arch Orthop Trauma Surg. 2008;128(7):695–9.

Xie L, Xu J, Sun X, Tang X, Yan T, Yang R, Guo W. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial. Oncologist. 2019;24(7):e542–50.

Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma – connecting aetiology, biology and therapy. Nat Rev Endocrinol. 2017;13(8):480–91.

Arora RS, Kontopantelis E, Alston RD, Eden TO, Geraci M, Birch JM. Relationship between height at diagnosis and bone tumours in young people: a meta-analysis. Cancer Causes Control. 2011;22(5):681–8.

Ognjanovic S, Olivier M, Bergmann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers: a review of the IMARc TP53 database. Cancer. 2012;118(5):1387–96.

Vlachos A, Rosenberg PS, Atsidafatos E, Kang J, Onel K, Sharaf RN, Alter BP, Lipton JM. Increased risk of colon cancer and osteogenic sarcoma in Diamond-Blackfan anemia. Blood. 2018;132(20):2205–8.

Maciaszek JL, Oak N, Chen W, Hamilton KV, McGee RB, Nuccio R, Mostafavi R, Hines-Dowell S, Harrison T, Taylor L, et al. Enrichment of heterozygous germline RECQL4 loss-of-function variants in pediatric osteosarcoma. Cold Spring Harb Mol Case Stud. 2019;5(5):a004218.

Chu WK, Hickson ID. RecQ helicases: multifunctional genome caretakers. Nat Rev Cancer. 2009;9(9):644–54.

Masliah-Planchon J, Lévy D, Héron D, Lévy GS, Bhatt AS, Rheinbay E, Pedamallu CS, et al. Complementary transcriptome RNA-seq data. Hum Genomics. 2014;8(1):20.

Fleuren EOD, Venterie M, van der Graaf WTA, Hillebrandt-Roeffen AMHS, Blackburn J, Ma X, Chan H, Magias MC, van Erp A, van Houdt L, et al. Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes. Cancer Res. 2018;78(17):4927–40.
41. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189–97.

42. Mossé YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, Adamson P, Wilner K, Blaney SM, Weigel BJ. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study. J Clin Oncol. 2017;35(28):3215–21.

43. Jiao XD, Liu K, Xu M, Yu G, Liu D, Huang T, Qin BD, Liu M, Wu Y, Ling Y, et al. Metastatic Low-Grade Sarcoma with CARS-ALK Fusion Dramatically Responded to Multiple ALK Tyrosine Kinase Inhibitors: A Case Report with Comprehensive Genomic Analysis. Oncologist. 2020;26(4):e524–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.